Xenon Pharmaceuticals Inc. (XENE) company profile
Close on Nov 17, 2026Market cap $3.76BP/E –Yield –
About Xenon Pharmaceuticals
Pharmaceutical Preparations, SIC 2834
The biopharmaceutical company specializes in discovering, clinically developing, and commercializing therapeutics aimed at treating neurological and psychiatric conditions. Its primary focus is on advancing ion channel modulators, featuring its lead investigational candidate, azetukalner, a Kv7 potassium channel opener evaluated in late-stage clinical trials for focal onset seizures, primary generalized tonic-clonic seizures, major depressive disorder, and bipolar depression. Additional early-stage programs target sodium and potassium channels for indications including pain and Dravet syndrome, alongside partnered research initiatives for epilepsy. The organization designs its therapies for patients suffering from difficult-to-manage central nervous system disorders.
The company's clinical research spans multinational sites across several countries, with trials enrolling patients in regions including the United States and Japan. In addition, its business activities involve strategic cross-border collaborations and licensing agreements with global pharmaceutical partners to advance select candidates worldwide. The provided text does not state the location of the company's corporate headquarters.
Summary of the business section of Xenon Pharmaceuticals's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Xenon Pharmaceuticals Inc.
- Founded
- 1996
- Headquarters
- Burnaby, British Columbia, Canada
- Address
- 200 - 3650 Gilmore Way
- Phone
- (604) 484-3300
- Website
- www.xenon-pharma.com
- Employees
- 370, Dec 31, 2025
- Industry
- Pharmaceutical Preparations
- Incorporated in
- A1
- Fiscal year ends
- December 31
- Auditor
- KPMG LLP, Vancouver, Canada
Stock & identifiers
- Ticker
- XENE
- Exchange
- Nasdaq
- IPO date
- Nov 5, 2014
- Shares outstanding
- 97M, Aug 3, 2026
- Public float
- $2.40B, Jun 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1582313
- CUSIP
- 98420N105
- ISIN
- CA98420N1050
- FIGI
- BBG0073DM784
- Share class FIGI
- BBG002VBMLS5
- LEI
- 549300XV44Q9Z1MIPQ03
- EIN
- 98-0661854
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ian Mortimer | PRESIDENT & CEO, Director | 64,223 |
| Thomas Patrick Kelly | Chief Financial Officer | 22,500 |
| Christopher John Kenney | Chief Medical Officer | 2 |
| Andrea DiFabio | Chief Legal Officer | 7,301 |
| Darren S. Cline | Chief Commercial Officer | 0 |
| Sherry Aulin | Chief Financial Officer | 0 |
| Dawn Svoronos | Director | 31,373 |
| Steven Gannon | Director | 1,870 |
| Gillian Cannon | Director | 1,455 |
| Gary Patou | Director | 29,798 |
| Elizabeth A. Garofalo | Director | 2,645 |
| Justin D. Gover | Director | 2,645 |
| Patrick Machado | Director | 2,645 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $9.22M | $11.49M | $3.57M | $291 | $120 |
| FY2024 | $9.80M | $4.35M | $4.14M | $255 | $91 |
| FY2023 | $10.12M | $13.87M | $3.06M | $299 | $92 |
| FY2022 | $9.23M | $13.95M | $3.18M | $256 | $89 |
| FY2021 Ian Mortimer | $3.89M | $8.16M | $1.97M | $203 | $99 |
| FY2021 Simon Pimstone | $4.12M | $9.97M | $1.97M | $203 | $99 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Ian Mortimer President and Chief Executive Officer | $786.00K | – | $1.77M | $6.07M | $550.20K | $46.26K | $9.22M | -6% |
| Thomas Kelly Chief Financial Officer | $114.55K | – | $1.26M | $5.81M | $51.55K | $5.97K | $7.24M | – |
| Darren Cline Chief Commercial Officer | $279.66K | – | – | $3.63M | $125.85K | $14.59K | $4.05M | – |
| Andrea DiFabio Chief Legal Officer and Corporate Secretary | $510.00K | – | $532.20K | $1.76M | $229.50K | $26.65K | $3.06M | -25% |
| Christopher Kenney Chief Medical Officer | $565.00K | – | $532.20K | $1.76M | $254.25K | $29.40K | $3.15M | -25% |
| Sherry Aulin Former Chief Financial Officer | $330.44K | $1.54K | – | – | – | $24.47K | $356.45K | -91% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Nov 5, 2014
- Offer price
- $9.00
- Securities offered
- 4,000,000
- Gross proceeds
- $36.00M
- Exchange
- Nasdaq
- First trading day
- Nov 5, 2014
- First-day close
- $10.50+16.7%
- Lock-up ends (est.)
- May 4, 2015
“The initial public offering price is $9.00 per common share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had 370 employees, including 358 full-time and part-time regular employees, of which 183 are located in Canada and 175 are located in the U.S.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 5, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 9, 2023 | Acquisition / sale | Completion of acquisition or disposition of assets (8-K Item 2.01) |
| Nov 5, 2014 | IPO | Initial public offering priced (424B4 prospectus) |
| Oct 10, 2014 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?